| 5.31 0.02 (0.38%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.41 |
1-year : | 7.49 |
| Resists | First : | 5.49 |
Second : | 6.41 |
| Pivot price | 5.1 |
|||
| Supports | First : | 4.75 |
Second : | 4.3 |
| MAs | MA(5) : | 5.23 |
MA(20) : | 4.95 |
| MA(100) : | 4.12 |
MA(250) : | 3.47 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 78.1 |
D(3) : | 76.9 |
| RSI | RSI(14): 62.1 |
|||
| 52-week | High : | 6.07 | Low : | 2.31 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PBYI ] has closed below upper band by 24.3%. Bollinger Bands are 23.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.5 - 5.52 | 5.52 - 5.55 |
| Low: | 5.1 - 5.13 | 5.13 - 5.15 |
| Close: | 5.27 - 5.3 | 5.3 - 5.35 |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Fri, 03 Oct 2025
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2025 - BioSpace
Thu, 11 Sep 2025
Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet? - simplywall.st
Tue, 02 Sep 2025
Biotech Leader Puma's CEO Alan Auerbach to Share Company Vision at H.C. Wainwright Global Conference - Stock Titan
Tue, 12 Aug 2025
Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT - Yahoo Finance
Tue, 12 Aug 2025
Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
Tue, 12 Aug 2025
Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out? - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 15.4 (%) |
| Held by Institutions | 68.3 (%) |
| Shares Short | 3,520 (K) |
| Shares Short P.Month | 2,770 (K) |
| EPS | 0.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.09 |
| Profit Margin | 20.3 % |
| Operating Margin | 12.6 % |
| Return on Assets (ttm) | 14.3 % |
| Return on Equity (ttm) | 63.2 % |
| Qtrly Rev. Growth | 11.3 % |
| Gross Profit (p.s.) | 3.41 |
| Sales Per Share | 4.72 |
| EBITDA (p.s.) | 1.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 44 (M) |
| Levered Free Cash Flow | 29 (M) |
| PE Ratio | 5.36 |
| PEG Ratio | 0 |
| Price to Book value | 2.52 |
| Price to Sales | 1.12 |
| Price to Cash Flow | 6.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|